<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04589624</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0482</org_study_id>
    <secondary_id>NCI-2020-05843</secondary_id>
    <secondary_id>2020-0482</secondary_id>
    <nct_id>NCT04589624</nct_id>
  </id_info>
  <brief_title>An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer Undergoing Radiation Therapy and/or Systemic Therapy</brief_title>
  <official_title>Pilot Study of Metabolic Guidance for Therapy in Patients With Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial investigates whether hyperpolarized magnetic resonance imaging (hpMRI) can predict&#xD;
      treatment response in patients with thyroid cancer undergoing radiation therapy and/or&#xD;
      receiving systemic therapy before surgery. An hpMRI is like a standard MRI but involves the&#xD;
      use of an imaging contrast agent called hyperpolarized 13-C-pyruvate. Diagnostic procedures,&#xD;
      such as hpMRI, may predict a patient's response to treatment and may help plan the best&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To obtain pilot metabolic imaging data from hyperpolarized magnetic resonance imaging&#xD;
      (hpMRI) methods in patients with thyroid tumors receiving radiation therapy (XRT) and/or&#xD;
      systemic therapy (e.g., target therapy, checkpoint inhibitors).&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To assess early metabolic changes in response to nonsurgical therapy, including&#xD;
      standard-of-care fractionated XRT and/or systemic therapy.&#xD;
&#xD;
      OUTLINE: Participants are assigned to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Healthy volunteers undergo MRI over 30 minutes.&#xD;
&#xD;
      ARM II: Patients with thyroid cancer undergo hpMRI over 30 minutes at baseline, and at 1 week&#xD;
      after the initiation of treatment. During the scan, patients also receive hyperpolarized&#xD;
      13-C-pyruvate intravenously (IV) over 30 seconds and may receive a standard MRI contrast&#xD;
      agent at the discretion of the treating physician.&#xD;
&#xD;
      After completion of study intervention, thyroid cancer patients are followed up at 1 day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic imaging data from hyperpolarized magnetic resonance imaging (hpMRI) methods</measure>
    <time_frame>1 year</time_frame>
    <description>To measure metabolic imaging data or information derived from hyperpolarized pyruvate MRI (hpMRI) that can be used to identify an early indication of response to therapy in patients with thyroid cancer. Specifically, we measure the kPL-the apparent rate constant for conversion of HP pyruvate into lactate-after one week of treatment compared to baseline measurements acquired prior to start of therapy. The kPL will be calculated from dynamic images of HP pyruvate and its metabolites. The kPL values will be calculated for each tumor and its adjacent tissue by a radiologist and physicist in conjunction using region of interest analysis to identify the margins of the tumor and surrounding normal tissue.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early metabolic changes</measure>
    <time_frame>1 year</time_frame>
    <description>To assess early metabolic changes in response to nonsurgical therapy, including standard-of-care fractionated XRT and/or systemic therapy. The imaging biomarker for tumor metabolism, kPL, will be calculated from dynamic images of HP pyruvate and its metabolites.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Thyroid Gland Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I ( Health Volunteer MRI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy volunteers undergo MRI over 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (Thyroid Cancer Patient hpMRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with thyroid cancer undergo hpMRI over 30 minutes at baseline, and at 1 week after the initiation of treatment. During the scan, patients also receive hyperpolarized 13-C-pyruvate IV over 30 seconds and may receive a standard MRI contrast agent at the discretion of the treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperpolarized Carbon C 13 Pyruvate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (Thyroid Cancer Patient hpMRI)</arm_group_label>
    <other_name>Hyperpolarized 13C-Pyruvate</other_name>
    <other_name>Hyperpolarized Pyruvate (13C)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo MRI</description>
    <arm_group_label>Arm I ( Health Volunteer MRI)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MR Imaging</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo hpMRI</description>
    <arm_group_label>Arm II (Thyroid Cancer Patient hpMRI)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MR Imaging</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be willing and able to provide informed consent&#xD;
&#xD;
          -  Be informed of the investigational nature of this study&#xD;
&#xD;
          -  Be diagnosed with thyroid cancer with intent for treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a history of severe claustrophobia&#xD;
&#xD;
          -  Have electrically, magnetically or mechanically activated implants that would preclude&#xD;
             magnetic resonance imaging (MRI)&#xD;
&#xD;
          -  Have a history of cardiac arrhythmia&#xD;
&#xD;
          -  Have an allergy to Gadavist intravenous contrast&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt; 30&#xD;
&#xD;
          -  If female, be pregnant or breast feeding at time of consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Y Lai</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen Y Lai</last_name>
    <phone>713-792-6528</phone>
    <email>sylai@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Y. Lai</last_name>
      <phone>713-792-6528</phone>
    </contact>
    <investigator>
      <last_name>Stephen Y. Lai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 10, 2020</last_update_submitted>
  <last_update_submitted_qc>October 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

